Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...

French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...

Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Recently, Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources… ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...

The deal will diversify the French beauty giant’s funding sources at a time when the industry is undergoing a slowdown.

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...